Skip to search formSkip to main contentSkip to account menu

Stage IV Renal Cell Cancer

Known as: Renal Cell Cancer Stage IV AJCC v6, Renal Cell Carcinoma, Stage IV AJCC v6, kidney cancer, stage IV 
Stage IV includes: (T4, N0, M0); (T4, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invades beyond Gerota's fascia. N0: No regional lymph… 
National Institutes of Health

Related topics

Related topics

19 relations
Epithelial CellsEpitheliumFlank PainHematuria

Broader (1)

Kidney Neoplasm

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Local therapy of stage IV renal cell cancer: a case report
SummaryThis mini-review and case report demonstrates how systemic and local treatments work synergistically for patients with… 
2017
2017
Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
2016
2016
Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?
In the 1990s, a debate raged about the benefit of cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). Many… 
2015
2015
Gene expression in primary and metastatic kidney cancer to discover drivers of metastasis and targets for drug development
Meeting abstracts An estimated 63,920 cases of kidney cancer will occur in the USA in 2015, and about 13,860 deaths will occur… 
2015
2015
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
BACKGROUND Current first-line treatments for metastatic renal cell carcinoma (mRCC) include the multityrosine kinase inhibitors… 
2014
2014
PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma.
TO THE EDITOR: Escudier et al recently published a report of the PISCES (Patient Preference Study of Pazopanib Versus Sunitinib… 
2014
2014
Reconciling the use of cytoreductive nephrectomy in the targeted therapy era.
2006
2006
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Lymphokine-activated killer (LAK) cells generated by high-dose continuous infusion interleukin-2 (IL-2) are able to… 
1997
1997
Reduction of brain metastasis following immunotherapy with interleukin-2 for stage IV renal cell cancer.
Advanced renal cell cancer (RCC) has a very poor prognosis, but a minority of patients can achieve objective responses after… 
1986
1986
Active immunotherapy of stage IV renal cell cancer using autologous tumor cells
SummaryA total of 53 patients with stage IV renal cell carcinoma were treated by vaccination with autologous tumor cells in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)